focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
You need your head checked also then if you think they’re ok!
The ceo is about to leave and we are none the wiser as to who or if they will replace her adding further uncertainty to this company!! And this is supposed to be acceptable??
They could release the best data ever known to man tomorrow and the market will still take no notice as this company is a mess from the inside out!!!
Imo we have a jumped up CEO who only cares about herself In charge(an offer she couldn’t refuse) and until she’s gone nothing is going to change. Let her go early and start to bring some organisation to this mess.
You do realise any inclination that data is bad then this is feeked!
Yes it’s very frustrating. I have watched a recent interview from Anne today and she needs to get her head checked she claims the company is in a better position now to when she joined imo it’s a feeking mess and she should be embarrassed it’s got so bad.
SORT THIS MESS OUT. It’s the least she could do for 10k a month.
They need to sort this stupid ceo issue out imo the chairman should become temporary replacement ASAP-announce to market!! Let do nothing Anne go ASAP she’s obviously not contributing anything the sooner we replace the better
They need to get their broker to write an update including explanation about CEO and new deals for nxp001 including how much revenue it will bring (if anything)
Start some basic PR even if it’s a few tweets from their twitter about current news on ipf or advances.
Anything is currently better than what you are doing-which is NOTHING!!! All in my opinion as a shareholder who has seen £132k plus turned into £65k !!!
It’s beyond a joke now!!
We are sorry, on this occasion NUFORMIX PLC could not facilitate your DDM request but looks forward to updating you at the next scheduled reporting period. DDM’s are at the sole discretion and availability of the company and that no conclusions should be made from a company declining a DDM, as defined in our terms of use policy.
Should you have any questions, please contact investorhelp@investormeetcompany.com.
Kind Regards,
The Team at Investor Meet Company
So what’s the point of them signing up to it??
Clinicians in the U.K. will now be able to prescribe the antifibrotic medicine Ofev (nintedanib) to people with non-idiopathic pulmonary fibrosis (PF) under a new decision by the National Institute for Health and Care Excellence (NICE).
That decision came following a five-year campaign led by the U.K. charity Action for Pulmonary Fibrosis — and supported by patients, families, and pulmonary disease specialists.
“This is a game changer for patients with progressive fibrosis,” Nazia Chaudhuri, PhD, a consultant respiratory physician at Manchester University National Health Service (NHS) Foundation Trust, said in a press release. “I am absolutely delighted with the NICE decision to be able to give life-changing antifibrotic therapy to all patients with progressive lung fibrosis.”
The NICE decision was welcomed by both patients and clinicians.
“This news means everything to me,” said Carol Fielding, a PF patient from Bolton, “It’s about seeing my young grandchildren reach more of their milestones and making some more memories for them. It’s about maybe living long enough that even the younger ones might remember me.”
https://pulmonaryfibrosisnews.com/2021/10/22/nice-agrees-to-allow-ofev-therapy-for-non-ipf-patients-in-uk/
Nfx Rns from March 2021
The study, performed in collaboration with the Newcastle Fibrosis Research Group, a top level multi-disciplinary research group of Newcastle University, UK, examined both the anti-fibrotic and anti-inflammatory potential of NXP002 in combination with the current SOC therapies, pirfenidone or nintedanib, using human precision cut lung slices taken from a single IPF donor.
The preliminary data from this study shows that the combination of NXP002 with SOC provided strong evidence of additional effects compared to either SOC alone on both fibrotic and inflammatory markers. In addition, the results showed evidence of similar or better activity of lower doses of SOC in combination with NXP002, compared to higher doses of SOC alone, indicating a potential for a dose-sparing effect of the combination. These data supplement the previously reported study of NXP002 in the same preclinical model where positive effects were seen when NXP002 was dosed alone and now there is strong data in combination with SOC therapy.
Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."
Will be us lot!!
Hate to say it but
The only explanation for the downward spiral must be someone privy to inside information selling why else?
More than £70k in the red now starting to get a little pee’ed off!!!
Come on bod pull your fingers out and do something anything must be better than nothing!!!
GLA!!
Agree that it’s crazy they’re currently valued higher than NFX.
A little bit of history on them though. They’re on their 3rd or 4th consolidation so lths there are massively in the red and most will need £2/3 just to break even. They don’t seem to have any interest in their products they have spent their investors money on. The market work on mysterious ways lol.
GLA!!
Let’s hope we don’t end up like them
“All pure speculation but given the uncertainty of our position and the fact that we won't have a CEO soon”
Correct pure speculation(I would say utter nonsense) uncertainty?? You’ll have to elaborate on that one as far as I’m aware we’re awaiting read outs on the 2 other drugs in the pipeline if positive both could generate licensing opportunities!! I’m sure it’s been addressed by the company that after data release they will look for a replacement ceo??
So other than post utter nonsense all day every day what is your agenda??
Soup many would think from your sudden change in stance maybe you’ve sold and now looking for a cheaper entry!!
“Secret backers” lol!!! Have a break think it’s all getting to your head!!!
When people buy the shares it will go up when they sell (like yesterday) it will continue to go down
Why do you feel the need to know this information other than bash the price even more what benefit would it make giving you the information you are crying out to know? What/why would you do with this information other than twist it into a negative narrative??
It’s not uncommon for companies to disclose amounts due to confidentiality agreements and competitive reasons.
All you lot would do is moan about the numbers anyway so why bother giving them to you?
Perplexed as to how ffx is know trying to negatively put down NXP002 although it has nothing to do with NXP001
The company now has an income stream it’s positive get a life you old moaning farts!!!
Next news NXP002 and NXP004 updates wait patiently or feck off!!!
“Traders”. ??
You are posting about yourself!
“Traders that thought the Ox deal would see buyers flocking in. Little research imo”.
Earlier post
Usual "undisclosed " lol. Investors obviously once again no right to know. Therefore probably nothing to shout about. And the ball very much on the Ox court.
Traded those I bought at 1.3p. Made a little, but was hoping for more.
This was never going to be a game changer for nfx, and as I said earlier, a deal just for the sake of it would be easily recognised as such by the markets.
And moaning about why it’s not going higher!!
“Traders”. ??
You are posting about yourself you muppet
“Traders that thought the Ox deal would see buyers flocking in. Little research imo”.
Earlier post
“Usual "undisclosed " lol. Investors obviously once again no right to know. Therefore probably nothing to shout about. And the ball very much on the Ox court.
Traded those I bought at 1.3p. Made a little, but was hoping for more.
This was never going to be a game changer for nfx, and as I said earlier, a deal just for the sake of it would be easily recognised as such by the markets.”
Conclusion
****** !!
It’s not nfx but it’s a preclinical study that shows inhalation is better than intravenously injections in the vein
In preclinical studies, PRS-220, Pieris Pharmaceuticals’ experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), showed stronger lung tissue penetration and anti-scarring effects than pamrevlumab — an into-the-vein, mechanistically similar IPF therapy currently being tested in a Phase 3 clinical trial.
These promising findings, which support Pieris’ plans to launch a Phase 1 trial of PRS-220 next year, were presented in a poster titled, “Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF,” at the European Respiratory Society International Congress 2021, held virtually Sept. 5–8.
“PRS-220 exemplifies our respiratory strategy of advancing programs addressing clinically-validated targets where a local approach may provide significant benefit to patients,” Shane Olwill, PhD, Pieris’ chief development officer, said in a press release.
Connective tissue growth factor (CTGF) is a protein found at higher-than-normal levels in the lung tissue of people with IPF. It contributes to the progressive and excessive tissue scarring (fibrosis) characteristic of the disease. As such, therapeutic approaches suppressing CTGF are thought to have the potential to prevent the activation of downstream pro-inflammatory and pro-fibrotic factors, thereby slowing or halting IPF progression.
In agreement, pamrevlumab — FibroGen’s experimental anti-CTGF antibody that is delivered directly into the bloodstream — was shown to safely and effectively slow lung function decline in IPF patients in a Phase 2 trial (NCT01890265).
https://pulmonaryfibrosisnews.com/2021/09/08/inhaled-prs-220-superior-into-the-vein-pamrevlumab-idiopathic-pulmonary-fibrosis-ipf-preclinical-data/
Preclinical studies show potential for single agent and combination use. Data from an in vitro IPF model has shown anti-fibrotic/anti-inflammatory activity of NXP002 alone and in combination with two approved IPF drugs. These studies suggest the addition of NXP002 may achieve the same or better activity at lower doses of the approved drugs, which may offer advantages as both have challenging side effects. Additional preclinical studies are planned as Nuformix builds out a more robust data package. Results due Q4 2021
Progress on NXP004. Research is also underway on developing new forms of an undisclosed marketed oncology drug (with sales c.$1.5bn in 2020). Results Due Q4 2021.
A patent filed in 2020 may be granted in 2022.
Licensing deal under negotiation with Oxilio. A licensing deal is being finalised with Oxilio, a private UK company, for NXP001, a novel formulation of aprepitant intended for cancer treatment. Licensing agreement could be announced anytime soon.
Indicative value NXP002
. We believe a licensing deal or partnership for NXP002 as a Phase 1-ready asset for IPF could have a $360-450m headline value, although the upfront would be likely to be in the $10-20m range. Although, the economics of such deals are difficult to predict, the future NPV of this asset alone could be +£50m.
Fully funded
Cash to 2023. Nuformix results show net cash of £1.6m, giving a runway into late CY2022
Question 7
Anne – are you more or less confident in the Company’s prospects than when you joined?
The Company is in a better position than when I joined – it is on a stronger financial footing with sufficient funds to do the planned studies with a runway beyond that. In addition, operational activities have been optimized and costs minimized, such that funds can be prioritized towards generating data on the portfolio assets to add to their value. The R&D work is progressing well for both NXP002 and NXP004 and I remain confident that these assets bring good opportunities
“ The R&D work is progressing well for both NXP002 and NXP004 and I remain confident that these assets bring good opportunities”
Fully funded and research progressing well!!!
GLA!!
The same bunch of idiots that spent most of last week in particular Friday crying like baby’s screaming for the release of the Q and A now saying it’s not good enough! You people are pathetic! Pretty predictable really
Average down or feck off you miserable old sods!!!
Q n a
https://nuformix.com/app/uploads/2021/08/NFX-AGM-2021-QA-27.08.21_Final.pdf